POLYMED - Investment Analysis: Buy Signal or Bull Trap?
Back to ListInvestment Rating: 3.4
| Stock Code | POLYMED | Market Cap | 12,573 Cr. | Current Price | 1,240 ₹ | High / Low | 2,938 ₹ |
| Stock P/E | 36.2 | Book Value | 285 ₹ | Dividend Yield | 0.28 % | ROCE | 18.2 % |
| ROE | 14.2 % | Face Value | 5.00 ₹ | DMA 50 | 1,430 ₹ | DMA 200 | 1,788 ₹ |
| Chg in FII Hold | -0.36 % | Chg in DII Hold | 0.31 % | PAT Qtr | 83.4 Cr. | PAT Prev Qtr | 89.0 Cr. |
| RSI | 39.2 | MACD | -46.7 | Volume | 1,28,527 | Avg Vol 1Wk | 1,48,847 |
| Low price | 1,210 ₹ | High price | 2,938 ₹ | PEG Ratio | 1.17 | Debt to equity | 0.08 |
| 52w Index | 1.75 % | Qtr Profit Var | -2.04 % | EPS | 33.8 ₹ | Industry PE | 33.2 |
📊 Analysis: Polymed shows moderate fundamentals with decent efficiency but faces valuation and profitability challenges. The company has ROE (14.2%) and ROCE (18.2%), which are healthy but not exceptional. EPS is ₹33.8, and quarterly PAT declined from ₹89 Cr. to ₹83.4 Cr. (-2.04%), showing slight earnings pressure. The P/E ratio of 36.2 is slightly above the industry average (33.2), suggesting mild overvaluation. The PEG ratio of 1.17 indicates valuations are reasonably aligned with growth. Dividend yield is modest at 0.28%. Debt-to-equity is low at 0.08, reflecting a strong balance sheet. Technically, the stock is weak, trading below both 50 DMA (₹1,430) and 200 DMA (₹1,788), with RSI at 39.2 and MACD negative (-46.7).
💰 Ideal Entry Price Zone: A good accumulation zone would be ₹1,200–₹1,250, close to recent lows (₹1,210). Current price (₹1,240) is within this zone, making cautious accumulation possible for long-term investors.
📈 Exit Strategy / Holding Period: For existing holders, Polymed can be held for 3–5 years given moderate fundamentals and low debt. Exit strategy should be considered near ₹1,500–₹1,600 if valuations stretch without earnings growth. Long-term holding is viable only if profitability stabilizes and growth momentum improves.
✅ Positive
- ROE (14.2%) and ROCE (18.2%) show decent efficiency.
- P/E ratio (36.2) is close to industry average (33.2).
- PEG ratio of 1.17 suggests valuations are aligned with growth.
- Debt-to-equity ratio is low at 0.08.
⚠️ Limitation
- Dividend yield modest at 0.28%.
- Quarterly PAT declined (-2.04%).
- Stock trading below both 50 DMA and 200 DMA.
📉 Company Negative News
- Quarterly PAT dropped from ₹89 Cr. to ₹83.4 Cr.
- FII holdings decreased (-0.36%).
- Weak technical indicators: RSI at 39.2, MACD at -46.7.
📈 Company Positive News
- DII holdings increased (+0.31%).
- Debt-to-equity ratio remains low, ensuring financial stability.
🏭 Industry
- Industry P/E at 33.2, slightly lower than Polymed’s valuation.
- Medical devices sector benefits from rising healthcare demand globally.
- Strong growth potential in exports and domestic healthcare infrastructure.
🔎 Conclusion
Polymed is moderately valued with decent efficiency metrics but faces profitability challenges and weak technicals. Ideal entry zone is ₹1,200–₹1,250. Existing holders can maintain positions for 3–5 years, with exit considered near ₹1,500–₹1,600 unless earnings growth improves sustainably.